The BioMedical Materials program (BMM) is a public private partnership, which aims to further strengthen the world-leading position of the Netherlands in the field of biomedical materials and applications. BMM is an initiative of leading Dutch industrial players, SMEs, charity foundations, academia, and a research institute. Biomedical materials will play a key role in enabling medical breakthroughs in healthcare, which are essential to meeting the increasing demand for more efficient and effective medical treatment. BMM will translate its breakthrough innovations into successful medical applications, intellectual property rights, and scientific publications.
Within the BMM program, PharmaCell BV participates in the SmartCare consortium. The aim of this consortium is to develop an autologous regenerative cellular approach for damaged myocardium, using cardiac progenitors. Those need to be expanded and possibly directed towards their first step of differentiation before being re-injected to the myocardium in a supportive biomaterial. In this consortium, that comprises of the universities of Utrecht and Leiden, DSM, Philips and a number of specialized SME’s, PharmaCell BV will develop the GMP culture of the cells and will advice on the regulatory issues that accompany the development of the carrier material and the loading of that material with the cells.